Novavax has signed a $1. 2 billion licensing agreement with Sanofi to commercialize a combination COVID-19 and flu vaccine.
Novavax will get $500 million in upfront bills, as well as another $700 million if all development, regulatory and launch milestones are met, according to a statement released Friday. Novavax, which will get tiered royalties on any vaccine sales, said Sanofi will also take a minority stake of about 5% in the U. S. company.
Your access to unlimited BenefitsPRO content does not change. Once you become a virtual ALM member, you will receive:
Already have an account? Sign in